arrow
H

Heiko Becker

faculty of medicine
H指数:40
被引数:7,964

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Precision oncology in advanced melanoma: molecular landscapes and personalized therapy recommendations from the Molecular Tumor Board Freiburg

高级黑色素瘤中的精准肿瘤学:来自弗赖堡分子肿瘤委员会的分子景观与个性化治疗建议

2026-10-210
OAAI
Author Correction: MAGE-A4/MAGE-A8-targeted TCR-based bispecific T cell engager in recurrent and/or refractory solid tumors: a phase 1 trial

作者更正:MAGE-A4/MAGE-A8靶向TCR基双特异性T细胞接合剂在复发和/或难治性实体瘤中的应用:一项1期临床试验

2026-06-190
OAAI
MAGE-A4/MAGE-A8-targeted TCR-based bispecific T cell engager in recurrent and/or refractory solid tumors: a phase 1 trial

MAGE-A4/MAGE-A8靶向TCR基T细胞连接器在复发和/或难治性实体瘤中的研究:一项1期临床试验

2026-05-310
OAAI
Clinical Impact of Molecular Tumor Board Inclusion on Treatment Outcomes in Neuroendocrine Neoplasms

分子肿瘤委员会纳入对神经内分泌肿瘤治疗结局的临床影响

2026-05-010
PRE
Comprehensive molecular profiling of urologic tumors presented in a molecular tumor board: insights from a real-world precision oncology cohort

泌尿系统肿瘤的全面分子特征分析:基于真实世界精准肿瘤学队列在分子肿瘤委员会中的呈现与启示

2025-11-270
OAAI
Genetic and epigenetic alterations at secondary resistance after continued decitabine-based treatment of acute myeloid leukemia in the randomized phase II DECIDER trial

随机II期DECIDER试验中,急性髓系白血病持续应用脱氧胞苷类似物为基础治疗后,获得性耐药时的遗传和表观遗传改变

Leukemia
IF13.4
2025-10-070
OA
ADORE: an open platform study of ruxolitinib in combination with other novel therapies in patients with myelofibrosis

ADORE:一项关于鲁索利替尼与其他新型疗法联合治疗骨髓纤维化患者的开放平台研究

2025-05-090
OAAI
European Cancer Organisation Essential Requirements for Quality Cancer Care: Hematological malignancies

欧洲癌症组织癌症护理质量基本要求:血液系统恶性肿瘤

2025-03-310
OAAI
Comprehensive genetic profiling and molecularly guided treatment for patients with primary CNS tumors
2024-08-140
OAAI
Oncogenic Calreticulin Induces Immune Escape by Stimulating TGFβ Expression and Regulatory T-cell Expansion in the Bone Marrow Microenvironment

致癌钙网蛋白通过刺激骨髓微环境中tgf β 表达和调节性T细胞扩增诱导免疫逃逸

2024-06-170
PRE
Inflammation plays an important role in the progression of chronic myeloid leukemia
2024-03-220
PRE
10-day decitabine versus 3+7 chemotherapy followed by allografting in older patients with acute myeloid leukaemia: an open-label, randomised, controlled, phase 3trial
2023-11-018
PRE
Mast cell deficiency prevents BCR::ABL1 induced splenomegaly and cytokine elevation in a CML mouse model

肥大细胞缺乏症可预防CML小鼠模型中BCR::ABL1诱导的脾肿大和细胞因子升高

LEUKEMIA
IF13.4
2023-05-091
OAAI
Activity of decitabine combined with all-trans retinoic acid in oligoblastic acute myeloid leukemia: results from a randomized 2x2 phase II trial (DECIDER)

地西他滨联合全反式维甲酸治疗少成细胞急性髓性白血病的活性: 一项随机2x2 II期试验 (DECIDER) 的结果

2023-01-050
OAAI